Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Clinical trial NCT05841472 · RECRUITING
Trial details
- NCT number
- NCT05841472
- Sponsor
- CrystalGenomics, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-23
- Primary completion
- 2026-08-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.